Elicio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. on August 30, 2023, covering events occurring on August 28, 2023. The Company is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on the Nasdaq Global Select Market under the symbol ELTX.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors, effective immediately. The Company stated that this resignation follows Mr. Segal's upcoming departure as Chief Executive Officer at Clal Biotechnology Industries. The filing explicitly notes that the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks, contingencies, or unusual items were disclosed in this report beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Assaf Segal resigned from the Board of Directors effective August 28, 2023.
- The resignation is linked to his departure from a separate role at Clal Biotechnology Industries.
- The Company confirmed no disagreement exists between Mr. Segal and the Company.
- Robert Connelly, President and CEO, signed the report on August 30, 2023.